Corcept’s Phase III Corlux Study Shows Promise

Corcept Therapeutics Inc. achieved positive results from its Phase III study of Corlux for the treatment of Cushing’s Syndrome. The study evaluated the response of two treatment groups: one in patients who were glucose intolerant and one in patients who were hypertensive. Statistically significant improvement in the primary endpoint was achieved in both groups, with 60% responding in the glucose intolerant group and 43% in the hypertensive group. Also, safety data indicates that Corlux was well tolerated by Cushing’s Syndrome patients.

“The results of the study demonstrate that Corlux has the potential to become an important treatment option for patients suffering from Cushing’s Syndrome,” said Joseph Belanoff, M.D., chief executive officer of Corcept. “We remain on track to submit a NDA to the FDA for Corlux in Cushing’s Syndrome by the end of the first quarter of 2011 and continue to work toward our goal of making Corlux available to patients with this severe disease.”